CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
By A. Trotti, A. Colevas, A. Setser, V. Rusch, D. Jaques, V. Budach, C. Langer, B. Murphy, R. Cumberlin, C. N. Coleman and 1 more. Seminars in Radiation Oncology, 2003
2,571 citations recorded by the source corpus.
Subfields: Neurology, Pediatrics, Perinatology and Child Health, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/d821db034317b1c2b70557ab23d279c37a7b17f9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
Citations in the corpus
- High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. (2009, neutral): “26 The worst toxic effects per organ, per patient were considered for analyses.”
- Chemotherapy‐induced peripheral neurotoxicity: A critical analysis (2013, methodology): “The most common CIPN assessments are clinicianadministered grading scales, including the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Neuropathy Sensory subscale (Table 2).(49) However, there is only a moderate level of interobserver agreement,(50) with 46% to”
- Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. (2014, neutral): “3) [11-89] 3 (3-5) [2-6] 10 (8-15) [6-30] 5 (5-7) [2-9] 4.”
- Stereotactic body radiation therapy for inoperable early stage lung cancer. (2010, methodology): “0 was used for grading adverse events.(13) Certain adverse events attributable to SBRT were specified prospectively within the protocol for use in evaluating the secondary end point of treatment-related toxicity.”
- Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). (2014, background): “Because the CTCAE requires reporting the “worst” magnitude of adverse events (29), the structure of the severity attribute items specified that the “worst” severity experienced should be recorded.”
- Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (2009, background): “0.(21) AEs included abnormal laboratory values relative to universal normal ranges.”